Cosentyx unoready 300 MG pen 2ML
Ended Awarded
- Contract number
- SPE2DR26FK173
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,985
Award facts
- Contract value 100% obligated
- $41,985.03 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $41,985.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Cosentyx (secukinumab) 300 mg pen auto-injectors in 2 mL formulations. This is a non-set-aside competitive award with an ultimate completion date of October 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This award for Cosentyx, an immunosuppressive biologic indicated for various autoimmune conditions, reflects AmerisourceBergen's role in ensuring consistent pharmaceutical supply to support military healthcare operations and readiness.
Quick answers
Who was awarded contract SPE2DR26FK173?
SPE2DR26FK173 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FK173 worth?
The government has obligated $41,985 on SPE2DR26FK173.
Is contract SPE2DR26FK173 an order under another contract?
Yes. SPE2DR26FK173 is a delivery order under SPE2DR25D1104, an indefinite delivery contract.
Was contract SPE2DR26FK173 competed?
The extent of competition for SPE2DR26FK173 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award